You may have recently seen an advertisement on television about Onglyza and the potential complications that are caused by taking the dangerous drug.

These commercials are airing because recent studies have identified this drug to have potentially dangerous and life threatening side effects, including heart attacks.

Several lawsuits have been filed in the past few months and many more are expected to follow in the coming months. Settlements in these cases are expected to be substantial.

If you or a loved one have suffered complications after taking this drug to manage diabetes, you may be entitled to a settlement for your suffering.

There are several complications that have been associated with the use of this drug. Some of the more serious side effects include heart attacks.

Our Onglyza Lawsuit Lawyers Can Help You

Our dangerous drug attorneys can help if you or someone you care about was harmed by Onglyza.

We are currently investigating claims against the pharmaceutical company by patients and their families seeking compensation for injuries caused by this dangerous drug. You may be entitled to a settlement.

Settlements are being sought for your pain and suffering and disability caused by the side effects of Onglyza. Compensation in these cases will also include medical expenses and loss if income.

Our No Fee Promise on Onglyza Lawsuits

You can afford to have our great team of lawyers on your side. When you choose us, it costs you nothing to get started. We promise you in writing:

  • No money to get started
  • We pay all case costs and expenses
  • No legal fees whatsoever unless you receive a settlement
  • Phone calls are always free

Start Your Onglyza Lawsuit

To get started on your claim, you can:

  1. Submit the Free Case Review Box on this page, or
  2. Call (866) 280-4722 any time of day to tell us about your case.

We will listen to your story and answer your questions. If you have a claim, we will start immediately.

WARNING: There are strict time deadlines for filing  Onglyza lawsuit claims.